For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The prostate is a walnut-sized gland located behind the base of a man's penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Scope of the Report:
The classification of Prostate Cancer Diagnostics includes Tumor Biomarker Tests, Imaging, Biopsy and other, and most of Prostate Cancer Diagnostics use the method of Biopsy, the proportion of Biopsy in 2017 is about 44.65%.
Prostate Cancer Diagnostics is widely used for the people with Prostate Cancer, The most proportion of Prostate Cancer Diagnostics is used for people with the age between 55 and 75, and the proportion is about 70.24% in 2017.
North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49.84% in 2017. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28% in 2017.
The worldwide market for Prostate Cancer Diagnostics is expected to grow at a CAGR of roughly 7.9% over the next five years, will reach 15800 million US$ in 2024, from 10000 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Prostate Cancer Diagnostics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Genomic Health
- Abbott
- OPKO
- Siemens Healthcare
- DiaSorin
- BioMeriux
- Roche
- MDx Health
- Beckman Coulter
- Myriad Genetics
- Ambry Genetics
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Tumor Biomarker Tests
- Imaging
- Biopsy
- Other
Market Segment by Applications, can be divided into
- age < 55
- age 55-75
- age > 75
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Prostate Cancer Diagnostics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Prostate Cancer Diagnostics, with price, sales, revenue and global market share of Prostate Cancer Diagnostics in 2017 and 2018.
Chapter 3, the Prostate Cancer Diagnostics competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Prostate Cancer Diagnostics breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Prostate Cancer Diagnostics market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Prostate Cancer Diagnostics sales channel, distributors, customers, research findings and conclusion, appendix and data source.